FDA Grants Accelerated Approval to Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-approval-lynozfic-linvoseltamab-rrmm)